The bad news clearly outweighed the good from Pfizer Inc.’s Phase IIb trial of its twice-daily, oral GLP-1 agonist danuglipron for obesity on 1 December, as the pharma said it would not advance the drug into Phase III in its current formulation. Pfizer still is holding out hope for a once-daily formulation it is developing, however, pointing to a pharmacokinetic data readout it expects during the first half of 2024.
Key Takeaways
-
Pfizer’s oral GLP-1 agonist danuglipron met statistical significance for weight loss in a Phase IIb study, but with a grim tolerability profile.
Danuglipron is Pfizer’s best hope for now at competing in the burgeoning obesity space, where Novo Nordisk A/S and...
